# Clinical Decision Biological Biomarker and Prognosis Prediction of Hepatocellular Carcinoma by Deep Learning

> **NCT05257694** · — · UNKNOWN · sponsor: **Ping Liang** · enrollment: 1 (estimated)

## Conditions studied

- Hepatocellular Carcinoma
- Contrast-enhanced Ultrasound
- Prognosis
- Surgery
- Ablation

## Interventions

- **PROCEDURE:** Surgery
- **PROCEDURE:** Ablation (Microwave ablation or Radiofrequency ablation)

## Key facts

- **NCT ID:** NCT05257694
- **Lead sponsor:** Ping Liang
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01-01
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 1 (ESTIMATED)
- **Last updated:** 2022-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05257694

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05257694, "Clinical Decision Biological Biomarker and Prognosis Prediction of Hepatocellular Carcinoma by Deep Learning". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05257694. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*